204 related articles for article (PubMed ID: 15127961)
21. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
22. Ondansetron, granisetron, and dexamethasone compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy : A randomized placebo-controlled study.
Erhan Y; Erhan E; Aydede H; Yumus O; Yentur A
Surg Endosc; 2008 Jun; 22(6):1487-92. PubMed ID: 18027038
[TBL] [Abstract][Full Text] [Related]
23. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Oge A; Alkiş N; Oge O; Kartum A
J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
[TBL] [Abstract][Full Text] [Related]
24. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
25. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Herrington JD; Kwan P; Young RR; Lagow E; Lagrone L; Riggs MW
Pharmacotherapy; 2000 Nov; 20(11):1318-23. PubMed ID: 11079280
[TBL] [Abstract][Full Text] [Related]
26. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
27. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
29. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
[TBL] [Abstract][Full Text] [Related]
30. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
32. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
[TBL] [Abstract][Full Text] [Related]
33. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Mabro M; Granisétron PK
Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764
[TBL] [Abstract][Full Text] [Related]
34. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin.
Birch R; Weaver CH; Carson K; Buckner CD
Bone Marrow Transplant; 1998 Oct; 22(7):685-8. PubMed ID: 9818697
[TBL] [Abstract][Full Text] [Related]
36. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
[TBL] [Abstract][Full Text] [Related]
37. Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Keat CH; Phua G; Abdul Kassim MS; Poh WK; Sriraman M
Asian Pac J Cancer Prev; 2013; 14(1):469-73. PubMed ID: 23534775
[TBL] [Abstract][Full Text] [Related]
38. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
Yarker YE; McTavish D
Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
[TBL] [Abstract][Full Text] [Related]
39. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
40. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]